348 related articles for article (PubMed ID: 25789840)
1. Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.
Su YL; Rau KM
J Thorac Oncol; 2015 Apr; 10(4):e21-2. PubMed ID: 25789840
[No Abstract] [Full Text] [Related]
2. Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases.
Kim YH; Mishima M
J Thorac Oncol; 2015 Aug; 10(8):e76. PubMed ID: 26200284
[No Abstract] [Full Text] [Related]
3. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological features of lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements].
Dong Y; Zhou L; Wang J; Cai Y; Mu J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):436-40. PubMed ID: 26463147
[TBL] [Abstract][Full Text] [Related]
5. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
6. Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.
Rusthoven CG; Doebele RC
J Clin Oncol; 2016 Aug; 34(24):2814-9. PubMed ID: 27298405
[TBL] [Abstract][Full Text] [Related]
7. ALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma.
Vaidya PJ; Kate AH; Mehta D; Dhabar BN; Chhajed PN
J Cancer Res Ther; 2016; 12(2):1090-2. PubMed ID: 27461706
[TBL] [Abstract][Full Text] [Related]
8. Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.
Jeong CJ; Lee HY; Han J; Jeong JY; Lee KS; Choi YL; Choi JY
Clin Nucl Med; 2015 Jan; 40(1):e34-9. PubMed ID: 25243942
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma.
Ilhan-Mutlu A; Osswald M; Liao Y; Gömmel M; Reck M; Miles D; Mariani P; Gianni L; Lutiger B; Nendel V; Srock S; Perez-Moreno P; Thorsen F; von Baumgarten L; Preusser M; Wick W; Winkler F
Mol Cancer Ther; 2016 Apr; 15(4):702-10. PubMed ID: 26809491
[TBL] [Abstract][Full Text] [Related]
10. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma.
Tao H; Cai Y; Shi L; Tang J; Liu Z; Wang Z; Bai L; Liu Z
Thorac Cancer; 2017 Jan; 8(1):8-15. PubMed ID: 27779369
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
[TBL] [Abstract][Full Text] [Related]
14. Changes in Immunohistochemical Protein Levels in Anaplastic Lymphoma Kinase-positive Lung Adenocarcinoma Possibly due to Chemo-radiotherapy.
Taniguchi H; Ikeda T; Soda H; Fukuda Y; Kitazaki T; Nakamura Y; Kohno S
Intern Med; 2016; 55(13):1775-8. PubMed ID: 27374682
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
16. Practice makes perfect protocols: the Canadian anaplastic lymphoma kinase study.
Yoshida A
J Thorac Oncol; 2014 Sep; 9(9):1237-9. PubMed ID: 25122418
[No Abstract] [Full Text] [Related]
17. Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH.
Heuckmann JM; Pauwels P; Thunnissen E
J Thorac Oncol; 2017 Mar; 12(3):e22-e24. PubMed ID: 28215724
[No Abstract] [Full Text] [Related]
18. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
[TBL] [Abstract][Full Text] [Related]
19. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
20. De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
Kim SH; Hyun JW; Kim HJ; Gwak HS; Lee SH; Hong EK; Lee Y
Lung Cancer; 2017 Aug; 110():53-55. PubMed ID: 28676219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
